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Background: The Aurora family of serine-threonine kinases are essential regulators of cell division in mammalian cells.
Aurora-A and –B expression and kinase activity is elevated in a variety of human cancers and is associated with
high proliferation rates and poor prognosis. AMG 900 is a highly potent and selective pan-aurora kinase inhibitor
that has entered clinical evaluation in adult patients with advanced cancers. In mice, oral administration of AMG
900 blocks the phosphorylation of histone H3 on serine-10 (p-Histone H3), a proximal substrate of aurora-B and
inhibits the growth of multiple human tumor xenografts, including multidrug-resistant models.
Methods: In order to establish a preclinical pharmacokinetic-pharmacodynamic (PK-PD) relationship for AMG 900
that could be translated to the clinic, we used flow cytometry and laser scanning cytometry detection platforms
to assess the effects on p-Histone H3 inhibition in terms of sensitivity, precision, and specificity, in human tumor
xenografts in conjunction with mouse skin and bone marrow tissues. Mice with established COLO 205 tumors
were administered AMG 900 at 3.75, 7.5, and 15 mg/kg and assessed after 3 hours.
Results: Significant suppression of p-Histone H3 in mouse skin was only observed at 15 mg/kg (p <0.0001), whereas in
mouse bone marrow and in tumor a dose-dependent inhibition was achieved at all three doses (p ≤0.00015). These
studies demonstrate that AMG 900 inhibits p-Histone H3 in tumors and surrogate tissues (although tissues such as skin
may be less sensitive for assessing PD effects). To further extend our work, we evaluated the feasibility of measuring
p-Histone H3 using fine-needle aspirate (FNA) tumor xenograft biopsies. Treatment with AMG 900 significantly
inhibited p-Histone H3 (>99% inhibition, p <0.0001) in COLO 205 tumors. Lastly, we illustrate this LSC-based approach
can detect p-Histone H3 positive cells using mock FNAs from primary human breast tumor tissues.
Conclusion: Phosphorylation of histone H3 is a useful biomarker to determine the pharmacodynamics (PD) activity of
AMG 900. FNA biopsies may be a viable approach for assessing AMG 900 PD effects in the clinic.
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The Aurora family of serine/threonine kinases is repre-
sented by three paralogous genes: Aurora-A, −B, and -C.
Despite a high degree of kinase domain similarity, the sub-
cellular localizations and functions of the auroras are pri-
marily non-overlapping. Aurora-A and -B play critical
roles during mitosis in chromosome segregation and cyto-
kinesis, while aurora -C function appears to be restricted
mainly to spermatogenesis. Aurora-A is reported to func-
tion as an oncogene capable of transforming rodent fibro-
blast cells in culture. The aurora-A gene (AURKA) locus
20q13 is amplified in a subset of cancers including: blad-
der, breast, colorectal, gastric, liver, ovarian, and pancre-
atic. In addition, aurora-A and -B expression is elevated in
a variety of human cancers, where their overexpression is
associated with advanced clinical staging and poor prog-
nosis [1-3].
Treatment of tumor cells with a small molecule inhibi-
tor targeting both aurora-A and -B causes premature mi-
totic exit without cell division [4]. The resulting undivided
4 N DNA-containing tumor cells can progress through
further rounds of DNA replication without division, a
process that ultimately induces cell death. This mechan-
ism of silencing the mitotic checkpoint through inhibition
of aurora-B (or dual inhibition of aurora-A and –B) is dis-
tinct from that of traditional anti-mitotic agents in that
cells do not pause or arrest in mitosis [4-7].
AMG 900, a novel ATP-competitive inhibitor of aurora
A/B/C, is active in a panel of human cancer cell lines,
including: colon, lung, prostate, breast, ovarian, uterine,
melanoma, kidney, liver, and hematologic with EC50 values
ranging from 0.7 to 5.3 nmol/L [8]. Phosphorylation of
histone H3 at serine-10 residue (p-Histone H3) is highly
correlated with the G2 to mitotis (M) cell cycle transition
and essential for chromatin condensation [9]. Given that
histone H3 is a direct target of aurora-B, measuring
serine-10 phosphorylation represents a measurement of
enzymatic activity [10]. Robust methodologies have been
developed for immunofluorescence based detection of
p-Histone H3 using multiparametric (coupled to DNA
content analysis) flow cytometry [11]. In mice oral admin-
istration of AMG 900 inhibits phosphorylation of histone
H3 in tumors and bone marrow in a concentration- and
dose-dependent manner. In order to further refine this
aurora-B biochemical biomarker, we evaluated the effects
of AMG 900 on p-Histone H3 in human tumor xeno-
grafts, mouse skin, and mouse bone marrow tissues
using both flow cytometry (FCM) and automated laser
scanning cytometry (LSC) detection platforms. Because
these preclinical studies had the potential to inform our
AMG 900 clinical biomarker program, we monitored
PD assay parameters (e.g. sensitivity, precision, and speci-
ficity) in tumor bearing mice (n = 10 per group). We dem-
onstrate that AMG 900 inhibits p-Histone H3 in tumorsand surrogate tissues. These findings support the use of
p-Histone H3 as a biomarker to determine plasma levels of
AMG 900 required to inhibit aurora-B activity. Notably,
mouse skin was not a particularly sensitive surrogate tissue
for assessing tumor PD effects as compared to the tumor
or the bone marrow. Therefore, we evaluated a transla-
tional approach to study on-target PD effects of AMG 900
using a more relevant biopsy method, fine needle aspirates
(FNAs) [12-14] to directly measure AMG 900 activity in
the tumor itself. For this proof-of-concept translational
study, we demonstrate that treatment with AMG 900
significantly reduced p-Histone H3 (>99% inhibition,
p <0.0001) in COLO 205 tumor FNAs, suggesting that
FNA biopsies may be a viable approach for assessing AMG
900 PD effects in the clinic. Lastly, we illustrate that this
LSC-based approach can detect p-Histone H3 positive cells






was synthesized at Amgen (WO2007087276). For in vivo
studies, AMG 900 was formulated as a suspension in 2%
HPMC, 1% Tween-80, at pH 2.2. Nocodazole was pro-
cured from Sigma-Aldrich.
Animal and cell line information
Female athymic nude mice (Harlan Sprague Dawley) of
approximately 14 weeks of age were housed five per steril-
ized filter-capped cages and maintained under aseptic and
pathogen-free conditions. The animal holding room pro-
vided 12 hours of alternating light and dark cycles and
met the standards of the Association for Assessment and
Accreditation of Laboratory Animal Care specifications.
Commercial rodent chow, filter-purified tap water was
offered ad libitum, and nutritional supplements were
provided daily. All animal studies were performed in
accordance with Amgen’s Institutional Animal Care
and Use Committee and U.S. Department of Agricul-
ture Regulations. All drugs were administered based on
the individual body weight of each mouse. Genetically
authenticated COLO 205 cells (human colorectal adeno-
carcinoma cell line) were procured from American Type
Culture Collection (ATCC). Cells were cultured in media
supplemented with 10% FBS using conditions specified by
ATCC.
COLO 205 tumor xenografts
Mice were injected subcutaneously with 2 ×106 COLO
205 cells in 100 μL of 50% matrigel (BD Biosciences).
Mice with established tumors (approximately 200 mm3)
were assigned into experimental groups (n = 10 per group)
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900 at 3.75, 7.5, and 15 mg/kg. Three hours after treat-
ment tissue specimens (bone marrow, tumor, and skin)
were collected from individual mice for pharmacodynamic
and histological analysis. Blood plasma samples (50 μL)
were collected from individual mice to determine the con-
centration of AMG 900 using quantitative methods previ-
ously described [15]. Excised tumors were divided in half
for parallel flow and imaging based cytometric analyses.
COLO 205 tumor and bone marrow p-Histone H3
assessment by FCM
Excised tumors were immediately minced into fine
pieces with a razor blade and transferred into 10 mL
of cell dissociation buffer [1XHBSS (Invitrogen),
0.1 mg/mL Collagenase-V (Sigma-Aldrich), 0.25 mg/mL
Collagenase-XI (Sigma-Aldrich), 1% Dispase II (Sigma-
Aldrich) and 25 units/mL RNase-free DNase I (Roche)]
in a 50 mL conical tube with a small magnetic stir
bar. Tubes were inverted and placed on a magnetic
stir plate for 30 minutes at 37°C with constant stir-
ring to facilitate dissociation into a single-cell suspen-
sion, and passed through 70 micron nylon filter (BD
Falcon) and centrifuged at 2000 rpm for four minutes
at 18°C. Tumor cell pellets were washed in 1 mL of
Versene (Invitrogen) and centrifuged at 2000 rpm for
one minute at room temperature. To finish, cell pel-
lets were fixed in ice-cold 90% methanol and stored
overnight at −20°C before immunocytochemical staining.
To isolate mouse bone marrow (BM) cells, trimmed femur
bone were flushed with 1 mL of BM harvest buffer [1X
HBSS, 1% BSA (Bovine Albumin Path-O-Cyte 5, ICN Bio-
medicals)] using 1 mL syringe, cells were centrifuged at
2000 rpm for one minute at 18°C, fixed in ice-cold 90%
methanol and stored overnight at −20°C before immuno-
cytochemical staining. Fixed tumor and bone marrow cells
(~1 ×106 cells/tube) were centrifuged at 2000 rpm for four
minutes and washed/permeabilized once with Wash
Buffer [1X PBS (Invitrogen), 1% BSA, 0.2% Triton X-100
(Sigma-Aldrich)]. Bone marrow cells were further proc-
essed by incubating the cells with 100 μL of Acid Buffer
(2 N HCl, 0.5% Triton X-100 in distilled water) for 45 mi-
nutes at room temperature. Cells were washed thrice in
Wash Buffer. Next, cells were stained with 2 μg/mL of
anti-p-Histone H3 serine-10 antibody (Millipore) and
30 μL per tube anti-cytokeratin-FITC antibody (COLO
205 tumors only, Clone 5D3, cytokeratin (8/18), Vector
Labs) for 1.5 hours at room temperature in the dark. After
centrifugation, cells were washed, and then stained with
1.5 μg/mL detection antibody (anti-rabbit IgG alexa-
647 second antibody, Invitrogen) for 45 minutes at room
temperature in the dark. Stained cells were centrifuged,
washed and counterstained with 200 μL of propidium iod-
ide (PI) supplemented with RNAse I (BD Biosciences) for30 minutes at room temperature in the dark, passed
through 35-micron nylon mesh filter and transferred
into 5 mL FACS tubes (Falcon) containing 400 μL of
PI. Data was acquired using a LSRII flow cytometer
running FACSDiva software (BD Biosciences Immunocy-
tometry Systems). A primary gating strategy was based on
DNA content (double discrimination) and a nested gate
on cytokeratin fluorescence intensity (COLO 205 tumors
only). A threshold gate was then applied on the G2M cell
population (4 N DNA content) and its corresponding p-
Histone H3 subpopulation (see Additional file 1: Figure
S1). The total percentage of p-Histone H3 positive events
in G2M was determined for each bone marrow and tumor
sample.
COLO 205 tumor and skin p-Histone H3 assessment by
LSC
As described above tumor and mouse tissues were col-
lected from each animal for p-Histone H3 analysis by LSC
including: half of each excised tumor, two skin punch bi-
opsies (left and right flanks), and small intestine as an in-
ternal proliferating tissue control. Tumor and tissues were
sectioned and then arrayed onto glass microscope slides.
After deparaffinization, rehydration, antigen retrieval, and
overnight blocking, slides were immunocytochemically
stained on an automated LabVision Autostainer 720™ [16].
Briefly, following five minutes of permeabilization with
0.2% Triton X-100 in 1X PBS, the slides were incubated in
blocking/staining buffer (1X PBS, 0.5% BSA, PBS/BSA) for
ten minutes at room temperature. Next, slides were incu-
bated in 2 μg/mL of anti-p-Histone H3 antibody in PBS/
BSA for 45 minutes. Slides were thoroughly rinsed in
PBS/BSA and stained with a secondary detection antibody
(2 μg/mL anti-rabbit IgG alexa-647) in PBS/BSA for 45 mi-
nutes. Slides were rinsed for ten minutes in PBS/BSA and
counterstained with the DNA dye DAPI (4′,6-Diamidino-
2 Phenylindole, Dihydrochloride) and mounted with glass
cover slips containing anti-fade reagent (Invitrogen). Data
was acquired using an iCys Laser Scanning Cytometer
(CompuCyte) and its affiliated iGeneration software (ver-
sion 3.2.4/3.3.1). Scanned images were obtained using a
20× objective to quantify the fluorescent intensity and
laser absorbance (light loss) signals for each specimen.
The tissue sections were scored using a two-step LSC-
protocol that automates the quantitation of p-Histone H3
positive events (counts) as a function of tissue area (mm2).
P-Histone H3 positive events were identified (contoured)
using long-red channel in high resolution scan mode.
Topological tissue maps were generated during data ana-
lysis by overlaying a lattice of small circles (10 micron ra-
dius) on top of the field images and mapping the density
of green autofluorescence or blue fluorescence (DNA
counterstain) inside each circle as a function of its x/y co-
ordinates. We mapped the p-Histone H3-positive cell
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function of their x/y coordinates (see Additional file 2:
Figure S2).COLO 205 tumor fine needle aspirates (FNAs) p-Histone
H3 assessment by LSC
Mice with established COLO 205 tumors (approxi-
mately 200 mm3) were administered a single oral dose
of vehicle alone or AMG 900 at 15 mg/kg. At three hours,
tumor aspirates (three replicates per tumor) were col-
lected for pharmacodynamic evaluation. Tumor aspirates
were collected by inserting a 25-gauge needle (BD Biosci-
ences) through a small incision in the skin surrounding
the tumor in a predetermined and consistent punch pat-
tern, and then expelled into 2% paraformaldehyde. Fixed
cell suspensions were spotted on microscope slides using
cytospin chambers and centrifugation (Shandon). As posi-
tive controls, COLO 205 cells in culture were treated with
DMSO or 100 ng/mL nocodazole for 16 hours and proc-
essed in the same manner as described for xenograft
tumors. Slides were immunocytochemically stained for p-
Histone H3 (alexa-647, CST) and counterstained with
DAP, as above. Images were acquired using an iCYS laser
scanning cytometry equipped with a 40× objective (high
resolution scan). Object segmentation was based on DNA
content (cell-cycle phase) and p-Histone H3 positive ob-
jects were verified by relocating images of mitotic object
into galleries. The percentage of p-Histone H3 positive
objects in G2M was determined for each FNA sample.Primary breast tumor fine needle aspirates p-Histone H3
assessment by LSC
Freshly resected human breast tumors were obtained
from Asterand (Detroit, MI) and Bio-Options (Fullerton,
CA) within 18 hours of surgery. Mock FNAs were
performed on breast tumors using a 22-gauge × 6-inch
Chiba needle (Becton Dickinson) attached to a 12-mL
syringe, and samples were deposited into a 2-mL tube
(Sarstedt) containing 1.5 mL of 4% paraformaldehyde.
Tubes were gently inverted five times to adequately sus-
pend the cells, and samples were stored at 4°C. Fixed cell
suspensions were spotted on microscope slides using
cytospin chambers and centrifugation (Shandon). Slides
were immunocytochemically stained with directly conju-
gated antibodies specific for EpCAM (epithelial tumor
marker, alexa-488, BD Biosciences) and p-Histone H3
(alexa-647, CST) and counterstained with DAPI, as above.
Images were acquired using an iCYS laser scanning cy-
tometry equipped with a 40× objective (high resolution
scan). Object segmentation was based on DNA content
(cell-cycle phase), and anti-EpCAM positivity. The au-
thenticity of the p-Histone H3 positive objects was verified
by relocating images of mitotic object into galleries.Statistical analysis
The effects on p-Histone H3 by AMG 900 and vehicle-
control treatment groups were compared using either
Oneway ANOVA followed by Dunnett’s post hoc ana-
lysis (Figure 1) or using ANOVA followed by Bonferroni
Dunnett’s post hoc analysis (Figure 2). Data were repre-
sented as the standard error of the mean (±SEM) for
each treatment group. Differences were considered sig-
nificant at a P value of <0.05. Graphing and linear re-
gression analysis was performed using GraphPad Prism
software.
Results
AMG 900 inhibits p-Histone H3 in COLO 205 human
tumor xenografts and mouse surrogate tissues as
measured by FCM and LSC
The primary objective of building a robust PK-PD rela-
tionship is to directly link drug exposure (e.g. dosage,
plasma concentration) to PD effect in desired target tis-
sue(s). Aurora-B kinase activity is essential for cell div-
ision [17]; therefore, normal and tumor proliferating
tissues are potentially suitable for assessing its enzymatic
activity. In order to examine the effects of aurora-B in-
hibition by AMG 900 in proliferating tissues (tumor,
bone marrow, and skin), we evaluated FCM and LSC cy-
tometric approaches to determine the level of p-Histone
H3 in single-cell tumor suspensions and tissue sections.
Mice with established COLO 205 tumors were adminis-
tered a single oral dose of vehicle alone or AMG 900 at
15, 7.5, and 3.75 mg/kg (n = 10 per group). We chose a
three hour post-dose time point for our PD assessment
[8]. As shown in Figure 1A, treatment with AMG 900 at
15 mg/kg significantly inhibited p-Histone H3 in the
G2M cell population in mouse bone marrow (upper
panel) and cytokeratin positive COLO 205 tumor (lower
panel) compared with vehicle-treated controls. Figure 1B
and C show the mean level of p-Histone H3 inhibition
by AMG 900 in bone marrow and tumor, respectively.
Oral administration of AMG 900 at 7.5 and 15 mg/kg
resulted in near maximal inhibition of p-Histone H3
(>85%, p <0.0001), whereas the lower dose of 3.75 mg/
kg showed partial but significant inhibition of p-Histone
H3 (>57%, p <0.0001). We also observed a correspond-
ing increase in total G2M cells in both bone marrow and
tumor in mice treated with AMG 900 (Figure 1D and E).
Next we tested the feasibility of using skin as a surrogate
tissue to assess the overall PD impact of AMG 900. Hair
follicle, skin, and oral buccal mucosa provide a non-
invasive source of proliferating normal cells (potential al-
ternative to more invasive bone marrow aspiration) that
may prove useful for establishing PK-PD relationship.
This approach was assessed in mice by comparing the
levels of p-Histone H3 in situ, in xenograft sections, in





Figure 1 AMG 900 inhibits p-Histone H3 and increases the percentage of G2M cells in a dose-dependent manner in COLO 205 tumors
and mouse bone marrow measured by Flow Cytometry (FCM). Mice bearing established tumors were orally administered a single dose of
vehicle alone or AMG 900 at 3.75, 7.5, or 15 mg/kg. Bone marrow and tumor specimens were collected three hours after treatment (n = 10 per
treatment group) and processed for p-Histone H3 and DNA content analysis by FCM. (A) Representative cell cycle profiles of bone marrow (upper
panel) and tumor (lower panel, COLO 205 tumor cells were identified using an anti-cytokeratin antibody). AMG 900 treatment decreases the p-Histone
H3 positive cell population in G2M detectable in the vehicle-treated control (blue, arrow). Column graphs represent the percentage of p-Histone H3
positive G2M cells (B and C) and G2M cells (D and E) for each treatment group (mean + SE). Statistical significance was determined by comparing the
individual AMG 900 treatment groups with vehicle-treated control (*P <0.0001).
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and evaluated by LSC. Sections of formalin-fixed paraf-
fin embedded xenograft tumors and skin biopsies were
immunocytochemically stained for p-Histone H3 as de-
scribed in the materials and methods section. We used
a stereological sampling methodology to quantify the
number of p-Histone H3 positive objects and reported
the data as a function of area (counts per mm2) [18]
(Additional file 2: Figure S2A). As shown in Figure 2A,
p-Histone H3 positive nuclei were detectable in both
mouse surrogate tissues (skin, hair follicle, small intes-
tine) and COLO 205 xenograft tumor. Staining with
anti-p-Histone H3 antibody produced a robust fluorescentsignal with low non-specific background. We also con-
firmed the mitotic specificity of p-Histone H3 positive ob-
jects using the relocation feature on the LSC; this creates
an image gallery of contoured objects (Additional file 2:
Figure S2B).
Having established the methods for detecting robust
p-Histone H3 staining using tissue and tumor xenograft
sections, we next evaluated the tumor and tissue sec-
tions treated with vehicle alone or AMG 900 as de-
scribed above. Mirroring our FCM based analysis, we
detected a marked decrease in p-Histone H3 positive
objects in COLO 205 tumors treated with AMG 900 at
15 and 7.5 mg/kg doses, whereas the lower dose of
Figure 2 AMG 900 inhibits p-Histone H3 in COLO 205 tumors and mouse skin (hair follicle, epidermis) in a dose-dependent manner
measured by Laser Scanning Cytometry (LSC). Mice bearing established tumors were orally administered a single dose of vehicle alone or AMG
900 (as described in Figure 1). Mouse skin specimens (a right- and left-flank punch biopsy from each animal) were collected three hours after treatment
(n = 10 per treatment group) and processed for p-Histone H3 analysis by LSC. Small intestine was also collected as a positive staining control for
p-Histone H3. Images were captured on a LSC (iCys, CompuCyte) using a 20× objective. See Materials and Methods Section for tissue and tumor section
immunofluorescence staining procedure and Additional file 2 Figure S2A for the random sampling contour strategy. (A) Representative scan fields of
mouse tissues (skin, hair follicle, small intestine) and COLO 205 tumor showing p-Histone H3 positive objects (red or pink). Nuclei were counterstained
with Hoechst 33342 (blue). An average p-Histone H3 object count (per mm2) was determined from three scan fields for each tissue section. Column
graphs represent p-Histone H3 positive object for skin (B) and COLO 205 tumor (C) (mean + SE). Statistically significant inhibition of p-Histone H3
compared with vehicle-treated control (*P <0.0001; **P =0.0005).
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(p ≤0.0005) (Figure 2C). The PD response in tumor mea-
sured by FCM and LSC were remarkably similar for AMG
900 dose groups (Figures 1C and 2C), suggesting that both
approaches are suitable for measuring p-Histone H3 in tu-
mors. The level of p-Histone H3 positive objects observed
in skin for the vehicle-control group was markedly lower
compared with tumor (roughly 10-fold lower), whereas
the fluorescence intensity of p-Histone H3 objects was
similar across skin and tumor. This lower frequency of mi-
totic objects observed in skin tissue is likely due to the
lower frequency of actively cycling cells in the basal layer
of the epidermis compared to more proliferative humantumor cells from xenograft tissue. Only mice treated with
AMG 900 at 15 mg/kg showed a statistically significant
suppression in p-Histone H3 (p <0.0001), indicating that
skin may be an unacceptable tissue for monitoring PD re-
sponse compared with either bone marrow or tumor tis-
sue sampling (Figure 2B).
In order to assess the PK-PD relationship, AMG 900
plasma levels were determined as described elsewhere
[19] for all three dosage groups and correlated with
bone marrow (FCM) and COLO 205 tumor PD re-
sponse (FCM and LSC). We included the vehicle
treated group as a PD baseline control. The PK-PD data
presented in Figure 3A-C shows the level of p-Histone
Figure 3 Mouse plasma concentration of AMG 900 correlates with the degree of p-Histone H3 suppression in both COLO 205 tumor
and mouse bone marrow tissues. Mice bearing established tumors were orally administered a single dose of vehicle alone or AMG 900 (as
described in Figure 1). Mouse plasma was collected three hours after treatment (n = 10 per treatment group). Scatter plots were generated using the
observed percentage of p-Histone H3 positive G2M cells for bone marrow (A) and COLO 205 tumor (B and C) and plasma concentration of AMG 900
(ng/mL) from individual mice. Treatment groups are indicated (○ vehicle, “green circle symbol” 3.75, “red circle symbol” 7.5, and ● 15 mg/kg).
Regression analysis was used to assess linearity of p-Histone H3 response relationship across tissue sets (D) FCM bone marrow versus tumor, (E) FCM
tumor versus LSC tumor. The correlation coefficient (R-squared value) and fitted line (red) are shown for each plot.
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tion of AMG 900 in mouse plasma using both FCM
and LSC platforms. The majority of test samples
with >1000 ng/mL (2 μM) plasma concentrations of
AMG 900 were associated with complete inhibition
of aurora-B activity as measured by the decrease in
p-Histone H3. In contrast, partial inhibition of p-Histone
H3 by AMG 900 (3.75 mg/kg group) was mostly associ-
ated with lower concentrations of drug (range 300 to
1000 ng/mL). Linear regression analysis of individual
paired PD responses were mostly concordant across tissues
[FCM, bone marrow versus tumor (R2 = 0.681, Figure 3D);
and FCM versus LSC, tumor (R2 = 0.662, Figure 3E)]. To-
gether, these data suggests that bone marrow is an accept-
able PD surrogate for tumor and that both FCM and LSC
approaches are sensitive and complimentary methods of
measuring aurora-B activity in vivo.AMG 900 inhibits p-Histone H3 in tumor cells using
fine-needle aspirate (FNA) biopsies
Fine-needle aspiration is an inexpensive biopsy tech-
nique used routinely for diagnosis [20,21] and has re-
cently been adapted for immunocytochemical analysis of
signal transduction pathways [12,13]. The LSC cytomet-
ric platform is well-suited for FNA sample analysis: 1) it
is capable of assessing small numbers of cells from com-
plex tissues such as tumor; 2) it retains the overall tumor
phenotype [12-14,22-25] Additional file 3: Figure S3A.
As shown in Figure 4A, COLO 205 tumor cells (in cul-
ture) can be identified in each phase of the cell cycle
(G1, S, G2M), with a subpopulation of p-Histone H3
positive in G2M with distinct condensed mitotic nuclei.
As anticipated, treatment with nocadozole (microtubule-
targeting agent), markedly increased the mitotic cell
fraction of p-Histone H3 positive objects. Cytometric
Figure 4 AMG 900 inhibits p-Histone H3 in COLO 205 tumor cells using fine-needle aspirate (FNA) biopsies. (A) LSC based in vitro cell
cycle assessment of COLO 205 tumor cells treated with DMSO or 100 ng/mL nocodazole. Cytospin deposited cells were immunostained with
an anti-p-Histone H3 antibody and counterstained with DAPI. Plots represent the cell cycle profile indicating G2M (arrow), and p-Histone H3
(red) subpopulations. Relocation gallery of representative scanned images of p-Histone H3 positive cells in mitosis. (B and C) Mice bearing
established COLO 205 tumors were orally administered a single dose of vehicle alone or AMG 900 at 15 mg/kg. Tumor FNA punch biopsies (n = 3 per
tumor) were collected three hours after treatment (n = 6 per treatment group) and processed for p-Histone H3 and DNA content analysis by LSC.
(B) Representative tumor FNA cell cycle profiles of vehicle (upper panel) and AMG 900 (lower panel) treatment groups. AMG 900 treatment completely
abolished the p-Histone H3 positive cell population in G2M detectable in the vehicle-treated control (red). (C) Scatter plot represents the individual and
mean percentage of p-Histone H3 positive G2M cells for each treatment group. Statistically significant inhibition of p-Histone H3 compared with
vehicle-treated control (*P <0.0001). COLO 205 tumor cells were treated with 100 ng/mL nocodazole (Nocod +) or DMSO (Nocod -) as p-Histone H3
staining controls. (D) Column graph represents vehicle-treated control group inter-(6 tumors) and intra-tumor FNA (3 per tumor) variation in the
percentage of p-Histone H3 positive G2M cells (mean + SE).
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objects was performed by using DNA content to restrict
analysis to single cells in the G2M phase.
As a proof-of-concept experiment designed to sup-
port the use of FNA sampling, mice with established
COLO 205 tumors (n = 6 per group) were administered
a single oral dose of vehicle alone or AMG 900 at
15 mg/kg. Tumor FNAs (n = 3 per tumor) were col-
lected three hours after treatment and immediately
fixed and processed for immunofluorescence staining
with an anti-p-Histone H3 antibody. Mice treated withAMG 900 showed near-complete inhibition of p-Histone
H3 in COLO 205 tumor FNAs compared with vehicle-
treated control (Figure 4B and C). Next, we obtained fresh
primary breast tumor tissue to evaluate the ability to de-
tect p-Histone H3 positive cells using the same FNA sam-
pling approach. To restrict our analysis to tumor cells, the
FNAs were co-stained with an anti-EpCAM antibody (epi-
thelial cell specific marker). As shown in Figure 5 (and
Additional file 3: Figure S3B), the EpCAM positive p-
Histone H3 G2M tumor cell population was readily de-
tectable in two mock FNA samples taken from the same
Figure 5 Detection of p-Histone H3 using primary human breast tumor FNA biopsies by LSC. Two mock FNA punch biopsies were
collected from the same fresh primary breast tumor tissue. Cytospin deposited cells were immunostained with anti-EpCAM antibody (epithelial
cell specific marker) and anti-p-Histone H3 antibodies and counterstained with DAPI. Representative cell cycle profiles of two FNAs showing
EpCAM positive (blue) tumor cells with a subpopulation of p-Histone H3 positive G2M cells (red). Relocation gallery showing p-Histone H3
positive objects.
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(<1%) p-Histone H3 objects was confirmed using the re-
location feature on the LSC (Figure 5, lower panel). The
frequency of p-Histone H3 positive cells in this primary
breast tumor was markedly lower compared to COLO
205 tumor xenografts. Taken together, these data indicate
that testing FNAs for p-Histone H3 immunoreactivity in
tumor cells is a viable approach to survey the PD activity
of AMG 900 in target tissues.
Discussion
Aurora kinases have emerged as attractive anticancer tar-
gets because of their key roles in regulating mitotic pro-
gression and associated aberrant expression in a number
of human malignancies [26-33]. Anti-mitotic drugs that
target the microtubules (e.g. taxanes and vinca alkaloids)have certain limitations that include MDR and peripheral
neuropathy [5,30]. To optimize the clinical development
of these promising drug candidates, efforts have been
made to identify and validate potential biomarkers, includ-
ing pharmacodynamic assessments in normal blood cells,
skin or/and tumor biopsies (reviewed in Perez-Fidalgo
et al. [27]).
The present preclinical report describes the efforts to
develop PD biomarkers that can be effectively translated
to the clinical setting for AMG 900. Specifically, our
studies address whether aurora-B activity is modulated
in tumor and surrogate tissues from animals treated with
AMG 900. Aurora-B plays a number of key roles in mi-
totic processes, including phosphorylation of histone H3
(necessary for chromosome condensation) and therefore,
measuring inhibition of phosphorylation of Histone H3
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[10]. Exploratory biomarker studies with different aurora
kinase inhibitor candidates in a clinical setting have been
used for both tumor and skin biopsies [7,34].
We investigated the feasibility of using mouse surro-
gate tissues (bone marrow and skin) to sample the over-
all PD impact of AMG 900 and directly compared the
effects to the levels of p-Histone H3 in tumor sections.
The baseline numbers of p-Histone H3 counts/mm2 in
skin tissue sections were markedly lower compared to
the tumor sections, whereas the immunoreactivity (MFI
signal) was similar. These data indicate that skin tissue
has a smaller fraction of actively cycling cells. Surpris-
ingly, only the higher dose of AMG 900 (15 mg/kg) ef-
fectively suppressed p-Histone H3 in the skin, whereas
the middle and lower doses of compound failed to show
a PD response, suggesting that skin may lack sufficient
sensitivity to use as a surrogate tissue readout. In con-
trast, measuring suppression of aurora-B activity in
tumor and bone marrow, provided similar levels of p-
Histone H3 inhibition, which may provide the transla-
tional possibility of detecting early evidence of drug
activity prior to clinical signs of tumor regression. One
possible explanation for the absence of a PD response
(at the lower doses of AMG 900) in skin is differences in
drug distribution in specific tissues, which was not de-
termined in this study.
We next adapted our sensitive, specific, and quantita-
tive PD assay for use with a non-invasive fine-needle
aspiration sampling technique using tumor xenograft
tissues. Our PD results obtained using FNAs was highly
concordant with dissociation or sectioned tumor xeno-
graft tissue, suggesting that FNAs may be a feasible ap-
proach for measuring on-target aurora-B inhibition in
tissue specimens in the clinic. Moreover, there was a
clear correlation between AMG 900 plasma exposure
and inhibition of p-Histone H3 in tumor cells. We con-
firmed the LSC cytometric platform was ideal for FNA
sample analysis, where it was capable of assessing small
numbers of mitotic cells from complex tissues such as
tumor FNAs. For example, the PD assessment of a
freshly resected breast tumor biopsy using a mock FNA
approach showed only a small fraction (<1%) of
EpCAM & p-Histone H3 positive objects. Because of
this limited number of tumor cells, it will be critically
important to have high quality tumor FNA samples to
obtain acceptable PD results using LSC analysis. Previ-
ously, we described pre-clinical and clinical implemen-
tation of another cytometric imaging assay that
measures activated caspase-3 using tumor FNAs [14,35].
It is important to note that phosphorylation of Histone
H3 can occur in all cell cycle phases during chromatin
condensation events such as premature chromosome
condensation [36], and in interphase during chromatinchanges accompanying monocytic lineage differenti-
ation [37]. Our approach restricted analysis to G2M cell
population, therefore it is unlikely that phosphorylation
of Histone H3 during interphase would interfere with
monitoring aurora-B activity in mitosis.
Conclusions
The present preclinical report describes the efforts to
effectively develop pharmacodynamic biomarkers that
can be translated to the clinical setting for AMG 900,
a small-molecule inhibitor of pan-aurora kinases.
p-Histone H3 measurement is a potentially useful
biomarker in clinical studies to determine plasma levels
of AMG 900 required to inhibit aurora-B activity. FNA
biopsies may be a viable approach for assessing AMG
900 PD effects in the clinic.
Additional files
Additional file 1: Figure S1. Flow cytometry gating scheme.
Representative bone marrow (A) and COLO 205 tumor (B) processed for
p-Histone H3 and DNA content analysis by FCM. Representative left plots to
identify single events and cell cycle vs p-Histone H3 profiles of bone marrow
(upper panel) and tumor (lower panel, COLO 205 tumor cells identified using
an anti-cytokeratin antibody). p-Histone H3 positive cell population in G2M
(blue).
Additional file 2: Figure S2. LSC segmentation scheme COLO205
tumor sections. Representative tumor xenograft section stained with DAPI
and anti-p-Histone H3 as assessed by laser scanning cytometry. (A) Image
analysis involved stereologic sampling of fields with a lattice of circular
contours to measure tumor area and cellular segmentation of positively
stained anti-p-Histone H3 events. p-Histone H3 events were unambiguously
labelled (left) and accurately contoured (middle). Topological tissue maps
were generated during data analysis by overlying a lattice of small
circles (r = 10 μm) on top of the field images (right). (B) Cytometric
gating quantitation (left), p-Histone H3 cell positions were mapped by
plotting all long red contoured events from the selected R1 gate as a
function of their x/y coordinates (middle) and positive p-Histone H3 events
were confirmed using image relocation galleries (right).
Additional file 3: Figure S3. LSC segmentation scheme Tumor FNAs.
(A) (Upper panel) Cytospun deposited COLO 205 FNAs were
immunostained with an anti-p-Histone H3 antibody and counterstained with
DAPI. Representative scanned image fields and cellular segmentation based
on DAPI (nuclear stain) and positive p-Histone H3 events (red). Lower panel
from left show representative cytometric gating plot to exclude aggregates
and identify single events, the cell cycle profile (middle plot), and p-Histone
H3 (red) in G2M cells (right plot). (B) Representative mock FNA from a human
primary breast tumor. Cytospun deposited FNAs were immunostained with
an EpCAM antibody, an anti-p-Histone H3 antibody and counterstained with
DAPI. Representative scanned image fields and cellular segmentation based
on DAPI (nuclear stain). Lower panel from left show representative cytometric
gating plot to identify EpCAM positive and negative events, the cell cycle
profile (middle plot) for both populations and and p-Histone H3 (red) in G2M
cells of EpCAM positive subset cells (right plot).
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